Amgen has secured a pivotal FDA clearance for its Rembra CT platform, enhancing its competitive edge in cancer treatment as it braves a challenging financial landscape. While facing a projected decline in earnings per share, the biopharmaceutical giant is also expanding its global footprint in Hong Kong and evaluating promising combination therapies that boost its stock performance. These strategic moves come in the wake of heightened market competition and impending patent expirations that threaten its established drug portfolio.
“According to OpenSecrets, Sen. Michael Bennet has received pharma/health product PAC donations including Pfizer ($10k), Merck ($17.5k), Amgen ($15k), AbbVie ($10k), plus nearly $1M total from health sector PACs over his Senate career.”
“$ZLAB (+2.4% pre) Zai Lab (ZLAB), Amgen $AMGN Partner to Evaluate Combination Lung Cancer Therapy; Zai Lab stock rises on positive trial data for cancer drug”
“Global drugmaker Pfizer and biotech firm Amgen, each valued at over HK$1T ($153B), are among 22 strategic enterprises planning to open or expand offices in Hong Kong, the South China Morning Post reported.”
“Axe Compute (AGPU) secured a $260 million, three‑year enterprise contract for a 2,304‑GPU NVIDIA B300 deployment, signaling sustained enterprise AI capacity buildouts.”
“Alpha Compute (ALP) executed a binding $31.9 million non‑recourse GPU financing backed by NVIDIA hardware, showing how financing markets are scaling to meet demand.”
“Philips (PHG) received FDA 510(k) clearance for its Rembra CT platform, expanding access to faster imaging across frontline care and oncology planning.”
“[Anheuser‑Busch (BUD)] pledged **$600 million** in U.S. manufacturing investment to target capacity and automation.”
“Lode Gold Submits Drill Permit Application at Fremont Gold Mine.”
“New PROG Holdings Research Offers Insight into Near- and Below-Prime Consumer Behavior.”
“Princess Cruises to Host Spectacular Alaska-Themed Drone Show from Seattle Center on May 1.”
“SOUTHERN MISSOURI BANCORP REPORTS PRELIMINARY RESULTS FOR THIRD QUARTER OF FISCAL 2026; DECLARES QUARTERLY DIVIDEND OF $0.25 PER COMMON SHARE”
“[REGN : Nasdaq] Dupixent® (dupilumab) Approved in the U.S. as the First Biologic Medicine for Young Children with Uncontrolled Chronic Spontaneous Urticaria (CSU)”
